Swiss Rockets' subsidiary RocketVax achieves milestone as its nasal COVID-19 vaccine RVX-sCPD9 is selected for the U.S. NIAID Project NextGen, advancing next-generation vaccine development.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.